Adenosine inhibits matrix metalloproteinase-9 secretion by neutrophils: Implication of A2a receptor and cAMP/PKA/Ca2+ pathway

Circulation Research

Volumn 99, Issue 6, 2006, Pages 590-597

  Ernens, Isabelle ^a   Rouy, Didier ^a   Velot, Emilie ^a   Devaux, Yvan ^a   Wagner, Daniel R ^b  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

Author keywords

Adenosine; Matrix metalloproteinase 9; Myocardial remodeling; Neutrophils; Protein kinase A

Indexed keywords

GELATINASE B;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; GENE SILENCING; HEART PROTECTION; HUMAN; HUMAN CELL; NEUTROPHIL; PRIORITY JOURNAL; SEDIMENTATION; ZYMOGRAPHY;

ADENOSINE; CALCIUM; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 9; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHIL ACTIVATION; NEUTROPHILS; RECEPTOR, ADENOSINE A2A; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 33748749963     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000241428.82502.d4     Document Type: Article

References (35)

1. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW, Flaker GC, Braunwald E, Pfeffer MA. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol. 2003;42:1446-1453.
2. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998;32:368-372.
3. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Sutherland P, Wilson PW, Vasan RS. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation. 2004;109:2850-2856.
4. Wagner D, Delagardelle C, Ernens I, Rouy D, Vaillant M, Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail. 2006;12:66-72.
5. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99:3063-3070.
6. Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, Lowry AS, Escobar GP, Lucas DG, Yarbrough WM, Zile MR, Spinale FG. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107:618-625.
7. Peterson JT, Li H, Dillon L, Bryant JW. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res. 2000;46:307-315.
8. Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P, Lyon R, Quinones M, Theroux P, Sydlowski D, Kim HE, Garcia MJ, Jaber WA, Weaver WD. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006;48:15-20.
9. Grisham MB, Hernandez LA, Granger DN. Adenosine inhibits ischemia-reperfusion-induced leukocyte adherence and extravasation. Am J Physiol. 1989;257:H1334-H1339.
10. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999;34:1711-1720.
11. Wagner DR, Combes A, McTiernan C, Sanders VJ, Lemster B, Feldman AM. Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-alpha. Circ Res. 1998;82:47-56.
12. Wagner DR, Kubota T, Sanders VJ, McTiernan CF, Feldman AM. Differential regulation of cardiac expression of IL-6 and TNF-alpha by A2-and A3-adenosine receptors. Am J Physiol. 1999;276:H2141-H2147.
13. Chen J, Tung CH, Allport JR, Chen S, Weissleder R, Huang PL. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation. 2005;111:1800-1805.
14. Rouy D, Ernens I, Jeanty C, Wagner DR. Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem. 2005;338:294-298.
15. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, Proost P, Van Damme J. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol. 2001;69:851-859.
16. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M. Plasma adenosine levels increase in patients with chronic heart failure. Circulation. 1997;95:1363-1365.
17. Barnes CR, Mandell GL, Carper HT, Luong S, Sullivan GW. Adenosine modulation of tumor necrosis factor-alpha-induced neutrophil activation. Biochem Pharmacol. 1995;50:1851-1857.
18. Selvatici R, Falzarano S, Mollica A, Spisani S. Signal transduction pathways triggered by selective formylpeptide analogues in human neutrophils. Eur J Pharmacol. 2006;534:1-11.
19. Schrier DJ, Imre KM. The effects of adenosine agonists on human neutrophil function. J Immunol. 1986;137:3284-3289.
20. McGarrity ST, Stephenson AH, Webster RO. Regulation of human neutrophil functions by adenine nucleotides. J Immunol. 1989;142:1986-1994.
21. Zhang Y, Palmblad J, Fredholm BB. Biphasic effect of ATP on neutrophil functions mediated by P2U and adenosine A2A receptors. Biochem Pharmacol. 1996;51:957-965.
22. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood. 1997;89:3503-3521.
23. Kohno Y, Ji X, Mawhorter SD, Koshiba M, Jacobson KA. Activation of A3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood. 1996;88:3569-3574.
24. Thiele A, Kronstein R, Wetzel A, Gerth A, Nieber K, Hauschildt S. Regulation of adenosine receptor subtypes during cultivation of human monocytes: role of receptors in preventing lipopolysaccharide-triggered respiratory burst. Infect Immun. 2004;72:1349-1357.
25. Olah ME, Gallo-Rodriguez C, Jacobson KA, Stiles GL. 125I-4-aminobenzyl- 5′-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol. 1994;45:978-982.
26. Visser SS, Theron AJ, Ramafi G, Ker JA, Anderson R. Apparent involvement of the A(2A) subtype adenosine receptor in the antiinflammatory interactions of CGS 21680, cyclopentyladenosine, and IB-MECA with human neutrophils. Biochem Pharmacol. 2000;60:993-999.
27. Gessi S, Varani K, Merighi S, Cattabriga E, Iannotta V, Leung E, Baraldi PG, Borea PA. A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol Pharmacol. 2002;61:415-424.
28. Bouma MG, Jeunhomme TM, Boyle DL, Dentener MA, Voitenok NN, van den Wildenberg FA, Buurman WA. Adenosine inhibits neutrophil degranulation in activated human whole blood: involvement of adenosine A2 and A3 receptors. J Immunol. 1997;158:5400-5408.
29. Jordan JE, Thourani VH, Auchampach JA, Robinson JA, Wang NP, Vinten-Johansen J. A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am J Physiol. 1999;277:H1895-H1905.
30. Murphree LJ, Marshall MA, Rieger JM, MacDonald TL, Linden J. Human A(2A) adenosine receptors: high-affinity agonist binding to receptor-G protein complexes containing Gbeta(4). Mol Pharmacol. 2002;61:455-462.
31. Zalavary S, Bengtsson T. Adenosine inhibits actin dynamics in human neutrophils: evidence for the involvement of cAMP. Eur J Cell Biol. 1998;75:128-139.
32. Sullivan GW, Rieger JM, Scheld WM, Macdonald TL, Linden J. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. Br J Pharmacol. 2001;132:1017-1026.
33. Lew PD, Monod A, Waldvogel FA, Dewald B, Baggiolini M, Pozzan T. Quantitative analysis of the cytosolic free calcium dependency of exocytosis from three subcellular compartments in intact human neutrophils. J Cell Biol. 1986;102:2197-2204.
34. Tintinger G, Steel HC, Anderson R. Taming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control. Clin Exp Immunol. 2005;141:191-200.
35. Spinale FG, Escobar GP, Hendrick JW, Clark LL, Camens SS, Mingoia JP, Squires CG, Stroud RE, Ikonomidis JS. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long term survival. J Pharmacol Exp Ther. 2006;318:966-973.